ISDA

Entry Detail

PDB ID:

6VEI

Keywords:

Title:

Crystal Structure of Human Cytosolic Isocitrate Dehydrogenase (IDH1) R132H Mutant in Complex with NADPH and AG-881 (Vorasidenib) Inhibitor

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2020-01-02

Release Date:

2020-02-05

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.10 Å

R-Value Free:

0.19

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 21 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Isocitrate dehydrogenase [NADP] cytoplasmic
Chain IDs:A, B
Chain Length:425
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O75874 Pfam ID:PF00180 EC:1.1.1.42

Ligand Molecules

33O

9UO

ACT

MLA

MLT

NDP

PEG

SO4

Primary Citation

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.

Konteatis, Z, Artin, E, Nicolay, B, Straley, K, Padyana, A.K, Jin, L, Chen, Y, Narayaraswamy, R, Tong, S, Wang, F, Zhou, D, Cui, D, Cai, Z, Luo, Z, Fang, C, Tang, H, Lv, X, Nagaraja, R, Yang, H, Su, S.M, Sui, Z, Dang, L, Yen, K, Popovici-Muller, J, Codega, P, Campos, C, Mellinghoff, I.K, Biller, S.A.Show

Acs Med.Chem.Lett. 11 101 107 (2020)

PMID: 32071674 DOI: 10.1021/acsmedchemlett.9b00509

Abstact

Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition. Furthermore, vorasidenib penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopic glioma mouse model. Vorasidenib represents a novel dual mIDH1/2 inhibitor and is currently in clinical development for the treatment of low-grade mIDH glioma.

Legend

Protein

Chemical

Disease

Primary Citation of related structures